<?xml version="1.0" ?>
<DOC>
   <DOCID>LA051394-0251</DOCID>
   <HEADLINE> BRIEFLY : OTHER NEWS</HEADLINE>
   <TEXT> Activase Value Questioned : An editorial in the current issue of the Annals of Internal Medicine said Genentech Inc. ' s heart_attack drug , genetically engineered tPA sold as Activase , is only slightly more effective than streptokinase -- which costs about one-tenth as much -- and should be used only on a limited basis . TPA has long been the subject of medical controversy over its advantages and cost.A House subcommittee was also reported to be looking_into a major 1993 study about the medication . Both drugs , known as thrombolytics or &quot; clot-busters , &quot; are given to patients shortly after a heart_attack . Genentech shares closed_down 62.5 cents at $ 46.125 on the New York Stock_Exchange after tumbling as low as $ 44 earlier in the day .</TEXT>
</DOC>
